Overview of Dr. Abuhadra
Dr. Nour Abuhadra is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from Weill Cornell Medical College in Qatar and has been in practice 1 year. She is one of 495 doctors at Memorial Sloan Kettering Cancer Center and one of 90 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. She has more than 20 publications and over 150 citings.
Office
300 East 66th Street
Floors 1 - 4
New York, NY 10065
Education & Training
Cleveland Clinic FoundationResidency, Internal Medicine, 2015 - 2018
Weill Cornell Medical College in QatarClass of 2015
Certifications & Licensure
FL State Medical License 2021 - Present
NY State Medical License 2021 - 2026
NJ State Medical License 2021 - 2025
OH State Medical License 2015 - 2018- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Susan Papizan Dolan Fellowship in Breast Oncology (Recognition of Research Excellence) University of Texas - MD Anderson Cancer Center, 2020
- ASCO Employees Conquer Cancer Foundation Merit Award American Society of Clinical Oncology, 2020
- Research Merit Award European Society Of Medical Oncology, 2020
- Join now to see all
Publications & Presentations
PubMed
- 24 citationsBeyond HER2: Targeting the ErbB receptor family in breast cancer.Joshua Z Drago, Emanuela Ferraro, Nour Abuhadra, Shanu Modi
Cancer Treatment Reviews. 2022-09-01 - 12 citationsImpact of TP53 mutations in Triple Negative Breast Cancer.Zahi I Mitri, Nour Abuhadra, Shaun M Goodyear, Evthokia A Hobbs, Andy Kaempf
NPJ Precision Oncology. 2022-09-09 - 6 citationsMolecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer.Clinton Yam, Nour Abuhadra, Ryan Sun, Beatriz E Adrada, Qing-Qing Ding
Clinical Cancer Research. 2022-07-01
Journal Articles
- Impact of social media for the hematologist/oncologist.Abuhadra, N et al, Seminars in Hematology, 10/1/2017
Abstracts/Posters
- Prognostic impact of high stromal tumor-infiltrating lymphocytes (sTIL) in the absence of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in early stag...Abuhadra, N et al, ASCO 2020, Chicago, IL. USA, 5/31/2020
- The Immunomodulatory (IM) Signature Enhances Prediction of Pathologic Complete Response (pCR) to Neoadjuvant Therapy (NAT) in Triple Negative Breast Cancers (TNBC) wit...Abuhadra, N et al, ESMO Breast Conference (Oral Presentation), Madrid, Spain (Virtual due to COVID-19), 5/1/2020
- Serial TILs: Evaluating the role of mid-treatment tumor infiltrating lymphocytes (TIL) in predicting pathologic complete response (pCR) in early-stage triple negative ...Abuhadra, N et al, San Antonio Breast Cancer Symposium, Texas, USA, 12/8/2019
- Join now to see all
Research History
- Developing patient selection strategies for chemotherapy de-escalation in early-stage triple-negative breast cancer.2018 - 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
